Table 1.
Basic information of included studies
| Study | Animal Models | Administration(dosage, time and route) | Evaluation methods of the treatment effectiveness test |
|---|---|---|---|
| He et al. [17] | Thirty 120-day APP/PS1 mice (male, 30) | 0, 50 and 100 mg/kg-berberine (n = 10 for each group), intragastric administration for 14 days. | MWM, WB analysis, immunohistochemistry |
| Chen et al. [18] | Aged 4–5 weeks Wistar rats weighting about 200 g memory-impairment diabetic Wistar Rats model (male) | DM group (diabetes mellitus), berberine group (187.75 mg/kg/d) and Met group (Metformin, 184 mg/kg/d), orally administration for 2 weeks. | Fear Condition, PET, WB analysis, immunochemistry |
| Huang et al. [19] | 4-month 3 × Tg-AD (male,18;female,18) | 0, 50 and 100 mg/kg berberine (n = 12 for each group), orally administration for 4 months. | MWM, platform recognition, HVS water maze, Aβ1–42: Elisa, WB analysis, Immunofluorescence staining, histological analysis |
| Oliveira et al. [20] | 300–350 g ICV-STZ induce sporadic Alzheimer’s-like dementia Wistar rats model (male, 60) | Control (CTR), berberine 50 mg/kg, berberine 100 mg/kg, streptozotocin, streptozotocin plus berberine 50 mg/kg, and streptozotocin plus berberine 100 mg/kg, orally administration for 21 days. | MWM, Elevated plus maze task, LDH: Labtest kit, AChE activity |
| Patil et al. [21] | 200–250 g memory-impairment Wistar rats model induced by ethanol (male,12) | 25, 50 and 100 mg/kg berberine, vitamin C (100 mg/kg), and vehicle (1 mL/kg), DDW control rats(double distilled water), orally administration (chronic treatment: once a day for 45 days before training; acute treatment: once a day for 5 days during training). | MWM, Memory consolidation test, Elevated plus maze test, ChE activity |
| Haghani et al. [22] | 200–250 g 60–65 days Aβ infused Wistar rats model (male, 32) | Sham(normal saline), berberine(50 mg/kg), Aβ(normal saline)and Aβ + berberine(berberine 50 mg/kg) (n = 8 rats in each group), intraperitoneal administration daily for 13 days. | MWM, Passive avoidance test, |
| Zhan et al. [23] | 180–220 g, 10–12 weeks D-galactose-induced memory impairment Wistar rats (male) | Berberine (100 mg/kg per day), orally administration for 7 weeks. | MWM, WB analysis, RT-PCR |
| Gao et al. [24] | 200–250 g (Pilo)-induced epilepsy Sprague Dawley rats (male,104) | 1) control group (n = 12), saline; 2) berberine 100 mg/kg group (n = 12); 3) Pilo group (n = 20); 4) Pilo + berberine 25 mg/kg group (n = 20); 5) Pilo + berberine 50 mg/ kg group (n = 20); 6) Pilo + berberine 100 mg/ kg group (n = 20). Orally administration daily for 7 days before Pilo injection. | MWM, GSH level: sectrophotometrical |
| Moghaddam et al. [25] | (STZ)-diabetic Wistar rats (male,50) | Control, berberine-treated control (100 mg/kg;), diabetic, and berberine-treated diabetics (50 and 100 mg/kg respectively). | Y-maze, Single-trial passive avoidance test, Electrophysiological experiments |
| Durairajan et al. [15] | TgCRND8 mice | Berberine (25 mg/kg per day), berberine (100 mg/kg per day), orally administeration | MWM, ELISA, Immunohistochemistry, WB analyses |
| Lee et al. [26] | 260–280 g SCO-induced memory deficits SD rats (male) | SAL group, PA group, SCO-induced and saline-treated group, SCO + berberine20 mg/kg group,SCO + PA100 group, SCO-induced plus 200 mg/kg PA-treated group, and the SCO-induced plus 0.2 mg/kg TA-treated group. Intraperitoneally administration once a day for 14 days. | MWM, Hidden platform trial, Probe trial, immunohistochemical, ELISA, |
| Bhutada et al. [27] | Memory-impairment diabetic Wistar rats (male) |
1.berberine (25, 50, 100 mg/kg), vitamin C (100 mg/kg), metformin (500 mg/kg), or vehicle (1 mL/kg) twice daily for 30 days. Orally administration 2.berberine (25, 50, 100 mg/kg), vitamin C (100 mg/kg), metformin (500 mg/kg), vehicle (1 mL/kg), twice daily during training trials for next 5 days. Orally administration |
MWM, Memory consolidation test, Open field test |
| Lim et al. [28] | Ibotenic acid-induced memory deficient Sprague Dawley rat model (male) | IBO model(saline), IBO model(berberine), saline injected sham group(berberine), daily Intraperitoneally administration for a week. | immunohistochemistry |
| Zhu et al. [29] | injected A-beta (1–40) (5 microgram) AD rat model | Berberine chloride (50 mg/kg), Orally administration once daily for 14 days. | MWM, immunohistochemistry, PCR |
| Peng et al. [30] | 200–250 g SCOP-induced amnesia Sprague-Dawley rats (male) | Berberine (0.1 and 0.5 g/kg) orally daily for 7-day or 14-day. | Passive avoidance response task, Motor activity measurements |
MWM, Morris water maze; WB analysis, Western Blot analysis; PET, Positron-Emission Tomography; RT-PCR, Reverse Transcription Polymerase Chain Reaction; AchE, Acethyl-cholinesterase; ICV-STZ, Intracerebroventricular streptozotocin; GSH, glutathione; Pilo, pilocarpine;